Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
Drug formulations and biologics make impressive gains
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated
